Product NDC: | 65862-313 |
Proprietary Name: | Didanosine |
Non Proprietary Name: | Didanosine |
Active Ingredient(s): | 400 mg/1 & nbsp; Didanosine |
Administration Route(s): | ORAL |
Dosage Form(s): | CAPSULE, DELAYED RELEASE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 65862-313 |
Labeler Name: | Aurobindo Pharma Limited |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA090094 |
Marketing Category: | ANDA |
Start Marketing Date: | 20080924 |
Package NDC: | 65862-313-50 |
Package Description: | 10 BLISTER PACK in 1 CARTON (65862-313-50) > 5 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK |
NDC Code | 65862-313-50 |
Proprietary Name | Didanosine |
Package Description | 10 BLISTER PACK in 1 CARTON (65862-313-50) > 5 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK |
Product NDC | 65862-313 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Didanosine |
Dosage Form Name | CAPSULE, DELAYED RELEASE |
Route Name | ORAL |
Start Marketing Date | 20080924 |
Marketing Category Name | ANDA |
Labeler Name | Aurobindo Pharma Limited |
Substance Name | DIDANOSINE |
Strength Number | 400 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |